Akebia Therapeutics Inc (AKBA)
1.82
+0.03
(+1.68%)
USD |
NASDAQ |
Nov 21, 16:00
1.81
-0.01
(-0.55%)
After-Hours: 20:00
Akebia Therapeutics Revenue (Quarterly): 37.43M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 37.43M |
| June 30, 2024 | 43.65M |
| March 31, 2024 | 32.61M |
| December 31, 2023 | 56.20M |
| September 30, 2023 | 42.05M |
| June 30, 2023 | 56.38M |
| March 31, 2023 | 40.00M |
| December 31, 2022 | 55.78M |
| September 30, 2022 | 48.71M |
| June 30, 2022 | 126.36M |
| March 31, 2022 | 61.70M |
| December 31, 2021 | 57.68M |
| September 30, 2021 | 48.76M |
| June 30, 2021 | 52.91M |
| March 31, 2021 | 52.30M |
| December 31, 2020 | 56.04M |
| Date | Value |
|---|---|
| September 30, 2020 | 59.99M |
| June 30, 2020 | 90.14M |
| March 31, 2020 | 88.48M |
| December 31, 2019 | 69.56M |
| September 30, 2019 | 91.98M |
| June 30, 2019 | 100.80M |
| March 31, 2019 | 72.67M |
| December 31, 2018 | 59.85M |
| September 30, 2018 | 53.17M |
| June 30, 2018 | 48.79M |
| March 31, 2018 | 45.93M |
| December 31, 2017 | 90.56M |
| September 30, 2017 | 41.28M |
| June 30, 2017 | 28.52M |
| March 31, 2017 | 20.86M |
| December 31, 2016 | 1.535M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
32.61M
Minimum
Mar 2024
126.36M
Maximum
Jun 2022
58.84M
Average
55.91M
Median
Revenue (Quarterly) Benchmarks
| Corcept Therapeutics Inc | 182.55M |
| Eli Lilly and Co | 11.44B |
| Bioventus Inc | 138.96M |
| NovaBay Pharmaceuticals Inc | 2.441M |
| Palatin Technologies Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -20.04M |
| Total Expenses (Quarterly) | 49.93M |
| EPS Diluted (Quarterly) | -0.10 |
| Enterprise Value | 401.43M |
| Gross Profit Margin (Quarterly) | 62.16% |
| Profit Margin (Quarterly) | -53.54% |
| Earnings Yield | -12.46% |
| Normalized Earnings Yield | -12.66 |